NRx Pharmaceuticals, Inc.
NASDAQ:NRXPBiotechnology
+$0.06 today
- Market cap
- $124.12M
- Beta
- 2.19
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$0.76
Volume 2.09M
Average 1.27M
NRXP Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
NRx Pharmaceuticals, Inc.NASDAQ: NRXP
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $3.71M rose 26.1% year over year, ahead of the +12.8% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 17.7% from the prior quarter. Over 3 fiscal years it compounded at -21.8% a year.
Context
- Selling, general & admin amounted to 1066.2% of revenue in FY2025.
- Selling, general & admin increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 3 analysts of $16.45M (+26.0%) for the fiscal year ending Dec 2026, a step up from the -3.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $3.71M-17.7% QoQ
- Last fiscal yearDec 2025
- $13.06M-3.3% YoY
- LTMMar 2026
- $13.76M+12.8% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 13.06M USD
- Year-over-year change
- -3.3%
- 4-year CAGR
- -35.4%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.06M | -3.3% |
| FY2024 | 2024-12-31 | 13.5M | -5.0% |
| FY2023 | 2023-12-31 | 14.21M | -48.0% |
| FY2022 | 2022-12-31 | 27.3M | -63.6% |
| FY2021 | 2021-12-31 | 74.94M | — |
Selling, General & Admin vs competitors
How NRXP compares with its peers on the latest reported figures
- NRXP's LTM Mar 2026 selling, general & admin of $13.76M is the 7th highest of the 9 companies compared; the peer median is $18.55M.
- Its year-over-year change of +12.8% is the 2nd highest of 9, against a peer median of +1.0%.
- Selling, general & admin amounts to 600.0% of revenue for NRXP, versus a peer median of 92.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $104.54M | -7.7% | -10.2% | 69.2% | |
| LTM Mar 2026 | $38.12M | -1.4% | +24.4% | 11443.7% | |
| LTM Mar 2026 | $22.18M | -32.4% | -9.0% | — | |
| LTM Jun 2026 | $19.35M | +4.7% | -9.7% | 92.1% | |
| LTM Mar 2026 | $17.75M | +26.9% | +12.0% | — | |
| LTM Mar 2026 | $16.21M | +11.3% | +0.2% | 49.5% | |
| LTM Mar 2026 | $13.76M | +12.8% | -21.8% | 600.0% | |
| LTM Mar 2026 | $10.46M | -6.1% | -14.5% | — | |
| LTM Mar 2026 | $8.86M | +3.4% | -29.6% | 626.3% | |
| Peer median (excluding NRXP) | $18.55M | +1.0% | -9.3% | 92.1% | |
Competitors are the stored peer set for NRXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 1.23M |
| Cost of Revenue | 2K | 4K | 5K | 5K | 505K |
| Gross Profit | (2K) | (4K) | (5K) | (5K) | 720K |
| Gross Margin | — | — | — | — | 58.8% |
| Research & Development | 20.26M | 17.03M | 13.37M | 6.2M | 3.78M |
| Selling, General & Admin | 74.94M | 27.3M | 14.21M | 13.5M | 13.06M |
| Operating Expenses | 95.2M | 44.33M | 27.58M | 19.7M | 16.94M |
| Depreciation & Amortization | 2K | 4K | 5K | 5K | 143K |
| EBITDA | (93.04M) | (39.75M) | (30.03M) | (24.04M) | (27.81M) |
| EBITDA Margin | — | — | — | — | -2270.0% |
| Operating Income | (95.2M) | (44.34M) | (27.59M) | (19.7M) | (16.22M) |
| Operating Margin | — | — | — | — | -1324.4% |
| Interest Income | 18 | 249K | 494K | 44K | 12K |
| Interest Expense | 18K | 0 | 120K | 1.08M | 671K |
| Other Income / Expenses | 2.14M | 4.58M | (2.56M) | (5.42M) | (12.4M) |
| Income Before Tax | (93.06M) | (39.75M) | (30.15M) | (25.13M) | (28.62M) |
| Pre-Tax Margin | — | — | — | — | -2336.5% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (93.06M) | (39.75M) | (30.15M) | (25.13M) | (28.62M) |
| Net Margin | — | — | — | — | -2336.5% |
| EPS (Basic) | (7.44) | (0.60) | (3.98) | (2.39) | (1.34) |
| EPS (Diluted) | (7.44) | (0.60) | (3.98) | (2.39) | (1.34) |
| Weighted Avg Shares | 46.92M | 65.77M | 7.58M | 10.52M | 21.4M |
| Weighted Avg Shares (Diluted) | 46.92M | 65.77M | 7.58M | 10.52M | 21.4M |
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
Intrinsic Alpha fair value
Locked
Current Price
$2.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.